Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)
Who can take part
Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.
You may be able to take part in this trial if you:
- are aged 18 years or older
- have high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancer
- have a tumour with high FRα expression (the researchers will test for this if you consent for the trial)
- have received prior treatment with a PARP inhibitor as maintenance therapy following first-line treatment (patients with somatic and germline BRCA gene variants only)
- have a recurrence of your ovarian cancer that is platinum-sensitive
- have had one previous line of chemotherapy for your ovarian cancer
This is not an exhaustive list. If you're interested in participating in a clinical trial, you should speak to your doctor about what other criteria might apply
About the trial
The trial is currently recruiting patients who have experienced a recurrence of ovarian, fallopian, or primary peritoneal cancer six months or more after receiving platinum-based chemotherapy.
Maintenance treatments (also known as targeted treatments)work on specific genes and proteins that are involved in the growth and survival of cancer cells. They are commonly used after first-line chemotherapy treatment for ovarian cancer to try and prevent or delay the cancer coming back (recurrence).
When a person's ovarian cancer comes back(recurs)more than 6 months after it was last treated with platinum-based chemotherapy (known as platinum-sensitive ovarian cancer) it is commonly treated with more platinum-based chemotherapy.
In the UK only women who haven't previously taken a parp inhibitor can have a maintenance treatment after this second line of chemotherapy is finished. In this trial, researchers are trying to find out if using Bevacizumab on its own or in combination with Mirvetuximab Soravtansine is effective and safe as a maintenance treatment in platinum-sensitive ovarian cancer.
The drugs involved in the trial are:
Bevacizumab is a targeted therapy that blocks a growth factor (like a hormone) that makes blood vessels. This growth factor is called VEGF. By blocking VEGF, some cancers in some patients can be starved of food and oxygen. This stops them from growing back again. Bevacizumab is usually given in addition to chemotherapy drugs and then on its own as a maintenance treatment. It is given intravenously (a drip into a vein.) There is evidence that Bevacizumab can be a useful maintenance treatment for platinum-sensitive ovarian cancer but it is not currently licensed for use in this way in the NHS.
Mirvetuximab Soravtansine is a type of targeted therapy: a folate receptor alpha (FRα) directed antibody combined with a microtubule inhibitor. It seeks out folate receptor α, a type of protein found on the surface of cancer cells. Once it locks onto these cells it uses a microtubule inhibitor to cause damage to the cancer cell's internal structure. After that, the cancer cell can no longer grow and dies. Mirvetuximab Soravtansine is licensed for use in platinum-resistant ovarian cancer(cancer that comes back less than 6 months after last treatment with platinum-based chemotherapy) in the United States but not in the UK. It is given intravenously (a drip into a vein.)
What happens if I take part in the trial?
If you are eligible for the trial and decide to take part you will receive treatment with chemotherapy and Bevacizumab. If at the end of the chemotherapy, your cancer has responded (got smaller or gone altogether) then you will be randomised (randomly allocated by a computer) into one of two groups:
Group One: Women in this group will receive maintenance Bevacizumab on its own
Group Two: Women in this group will receive maintenance Bevacizumab and Mirvetuximab Soravtansine
You can stay on the study for as long as your cancer is not getting worse.
This information was last reviewed on 29/02/2024. Please note that the status of clinical trials can change at short notice. You should always check with your clinical team which trials may be suitable for your situation.
